HRP20221098T1 - Tretman kognitivnih i simptoma poremećaja raspoloženja kod neurodegenerativnih i neuropsihijatrijskih poremećaja agonistima gabaa receptora koji sadrže alfa5 - Google Patents
Tretman kognitivnih i simptoma poremećaja raspoloženja kod neurodegenerativnih i neuropsihijatrijskih poremećaja agonistima gabaa receptora koji sadrže alfa5 Download PDFInfo
- Publication number
- HRP20221098T1 HRP20221098T1 HRP20221098TT HRP20221098T HRP20221098T1 HR P20221098 T1 HRP20221098 T1 HR P20221098T1 HR P20221098T T HRP20221098T T HR P20221098TT HR P20221098 T HRP20221098 T HR P20221098T HR P20221098 T1 HRP20221098 T1 HR P20221098T1
- Authority
- HR
- Croatia
- Prior art keywords
- alpha5
- neurodegenerative
- cognitive
- treatment
- receptor agonists
- Prior art date
Links
- 102000027484 GABAA receptors Human genes 0.000 title 1
- 108091008681 GABAA receptors Proteins 0.000 title 1
- 230000001149 cognitive effect Effects 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000036651 mood Effects 0.000 title 1
- 230000000626 neurodegenerative effect Effects 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 208000024891 symptom Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662310409P | 2016-03-18 | 2016-03-18 | |
| EP17767701.0A EP3439665B1 (en) | 2016-03-18 | 2017-03-20 | Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with alpha5-containing gabaa receptor agonists |
| PCT/US2017/023206 WO2017161370A1 (en) | 2016-03-18 | 2017-03-20 | Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with alpha5-containing gabaa receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20221098T1 true HRP20221098T1 (hr) | 2022-11-25 |
Family
ID=59851645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20221098TT HRP20221098T1 (hr) | 2016-03-18 | 2017-03-20 | Tretman kognitivnih i simptoma poremećaja raspoloženja kod neurodegenerativnih i neuropsihijatrijskih poremećaja agonistima gabaa receptora koji sadrže alfa5 |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US10906909B2 (https=) |
| EP (2) | EP3439665B1 (https=) |
| JP (2) | JP7023876B2 (https=) |
| AU (2) | AU2017235665B2 (https=) |
| CA (1) | CA3016491A1 (https=) |
| CY (1) | CY1125576T1 (https=) |
| DK (1) | DK3439665T3 (https=) |
| ES (1) | ES2926918T3 (https=) |
| HR (1) | HRP20221098T1 (https=) |
| HU (1) | HUE059774T2 (https=) |
| LT (1) | LT3439665T (https=) |
| PL (1) | PL3439665T3 (https=) |
| PT (1) | PT3439665T (https=) |
| RS (1) | RS63674B1 (https=) |
| SI (1) | SI3439665T1 (https=) |
| SM (1) | SMT202200372T1 (https=) |
| WO (1) | WO2017161370A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7013446B2 (ja) | 2016-08-16 | 2022-02-15 | ユーダブリューエム・リサーチ・ファウンデーション，インコーポレーテッド | Ｇａｂａ（ａ）受容体モジュレーター、及び、喘息における気道過敏及び炎症を抑制するための方法 |
| US20220105106A1 (en) * | 2019-02-13 | 2022-04-07 | Centre For Addiction And Mental Health | Compositions and methods relating to use of agonists of alpha5-containing gabaa receptors |
| SG11202109526PA (en) * | 2019-03-18 | 2021-10-28 | Neurocycle Therapeutics Inc | Use of gabaa receptor modulators for treatment of pain |
| TWI901650B (zh) | 2020-03-26 | 2025-10-21 | 匈牙利商羅特格登公司 | 啶及吡啶并〔３，４－ｃ〕嗒衍生物 |
| US20240374612A1 (en) * | 2021-09-08 | 2024-11-14 | Uwm Research Foundation, Inc. | Imidazobenzodiazepines for treatment of cognitive and mood symptoms |
| HU231691B1 (hu) | 2021-09-29 | 2025-10-28 | Richter Gedeon Nyrt | GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok |
| AU2022359461A1 (en) * | 2021-10-07 | 2024-05-02 | Pantherics Incorporated | Methods and compounds for treating inflammation |
| WO2024077061A2 (en) * | 2022-10-04 | 2024-04-11 | Uwm Research Foundation, Inc. | Gaba(a) receptor modulators and methods to control smooth muscle contraction and inflammation |
| IT202400001089A1 (it) * | 2024-01-22 | 2025-07-22 | Fondazione St Italiano Tecnologia | Composti e composizioni per l'uso nel ripristino di deficit cognitivi e comportamentali e nel miglioramento della memoria di individui nati pretermine |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA755418B (en) * | 1974-09-11 | 1977-06-29 | Hoffmann La Roche | Diazepine derivatives |
| US4226768A (en) | 1979-05-29 | 1980-10-07 | Hoffmann-La Roche Inc. | Process for the preparation of imidazobenzodiazepines |
| US20030176456A1 (en) | 2001-12-21 | 2003-09-18 | June Harry L. | Methods for reducing alcohol cravings in chronic alcoholics |
| USRE47475E1 (en) | 2002-03-28 | 2019-07-02 | Wisys Technology Foundation, Inc. | Selective agents for pain suppression |
| US8835424B2 (en) | 2002-03-28 | 2014-09-16 | Wisconsin Alumni Research Foundation | Selective agents for pain suppression |
| DE60319812T2 (de) | 2002-03-28 | 2009-04-23 | Wisys Technology Foundation, Inc., Madison | Angstlösende wirkstoffe mit verminderten beruhigenden und ataktischen nebenwirkungen |
| CA2570185A1 (en) | 2004-06-30 | 2006-01-12 | Wisys Technology Foundation Inc. | Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects |
| US20100130479A1 (en) | 2005-05-16 | 2010-05-27 | Cook James M | Gabaergic Agents to Treat Memory Deficits |
| EP1888594A2 (en) | 2005-05-16 | 2008-02-20 | Wisys Technology Foundation, Inc. | Gabaergic agents to treat memory deficits |
| WO2007042544A2 (en) | 2005-10-14 | 2007-04-19 | Neurosearch A/S | Imidazole derivatives and their use for modulating the gabaa receptor complex |
| DE102006023554A1 (de) | 2006-05-19 | 2007-11-22 | Zf Friedrichshafen Ag | Ermittlung der Drehzahl einer Getriebewelle |
| US8119629B2 (en) | 2007-10-03 | 2012-02-21 | Bristol-Meyers Squibb Company | Carboxamide GABAA α2 modulators |
| EP2364571B1 (en) | 2008-10-02 | 2012-08-22 | Telefonaktiebolaget L M Ericsson (PUBL) | Wireless communication system and method for assigning a channel in said wireless communication system |
| US20100261711A1 (en) | 2009-03-20 | 2010-10-14 | Wisys Technology Foundation | Selective anticonvulsant agents and their uses |
| US9006233B2 (en) | 2011-04-28 | 2015-04-14 | Uwm Research Foundation, Inc. | Gabaergic receptor subtype selective ligands and their uses |
| CA2885148A1 (en) | 2012-09-21 | 2014-03-27 | Uwm Research Foundation, Inc. | Novel gabaa agonists and methods of using to control airway hyperresponsiveness and inflammation in asthma |
| CA2979701C (en) | 2015-03-20 | 2023-01-03 | Uwm Research Foundation, Inc. | Oxazole substituted benzimidazodiazepines and their uses as gabaergic ligands |
-
2017
- 2017-03-20 DK DK17767701.0T patent/DK3439665T3/da active
- 2017-03-20 PT PT177677010T patent/PT3439665T/pt unknown
- 2017-03-20 HR HRP20221098TT patent/HRP20221098T1/hr unknown
- 2017-03-20 CA CA3016491A patent/CA3016491A1/en active Pending
- 2017-03-20 RS RS20220892A patent/RS63674B1/sr unknown
- 2017-03-20 AU AU2017235665A patent/AU2017235665B2/en active Active
- 2017-03-20 WO PCT/US2017/023206 patent/WO2017161370A1/en not_active Ceased
- 2017-03-20 SI SI201731230T patent/SI3439665T1/sl unknown
- 2017-03-20 PL PL17767701.0T patent/PL3439665T3/pl unknown
- 2017-03-20 ES ES17767701T patent/ES2926918T3/es active Active
- 2017-03-20 US US16/086,053 patent/US10906909B2/en active Active
- 2017-03-20 JP JP2018568186A patent/JP7023876B2/ja active Active
- 2017-03-20 EP EP17767701.0A patent/EP3439665B1/en active Active
- 2017-03-20 EP EP22181243.1A patent/EP4129297A1/en active Pending
- 2017-03-20 SM SM20220372T patent/SMT202200372T1/it unknown
- 2017-03-20 LT LTEPPCT/US2017/023206T patent/LT3439665T/lt unknown
- 2017-03-20 HU HUE17767701A patent/HUE059774T2/hu unknown
-
2020
- 2020-12-15 US US17/122,745 patent/US11753412B2/en active Active
-
2022
- 2022-02-08 JP JP2022017827A patent/JP7515526B2/ja active Active
- 2022-09-27 CY CY20221100636T patent/CY1125576T1/el unknown
- 2022-11-23 AU AU2022275446A patent/AU2022275446B2/en active Active
-
2023
- 2023-08-02 US US18/363,933 patent/US12180216B2/en active Active
-
2024
- 2024-11-12 US US18/944,947 patent/US20250179080A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| LT3439665T (lt) | 2022-10-10 |
| PT3439665T (pt) | 2022-09-27 |
| US12180216B2 (en) | 2024-12-31 |
| AU2017235665B2 (en) | 2022-12-08 |
| WO2017161370A1 (en) | 2017-09-21 |
| EP3439665A1 (en) | 2019-02-13 |
| DK3439665T3 (da) | 2022-09-26 |
| JP2019509340A (ja) | 2019-04-04 |
| AU2022275446B2 (en) | 2025-01-02 |
| RS63674B1 (sr) | 2022-11-30 |
| AU2022275446A1 (en) | 2023-01-05 |
| EP3439665A4 (en) | 2019-11-27 |
| JP2022065035A (ja) | 2022-04-26 |
| SMT202200372T1 (it) | 2022-11-18 |
| PL3439665T3 (pl) | 2023-01-16 |
| CA3016491A1 (en) | 2017-09-21 |
| SI3439665T1 (sl) | 2023-05-31 |
| US11753412B2 (en) | 2023-09-12 |
| EP4129297A1 (en) | 2023-02-08 |
| EP3439665B1 (en) | 2022-06-29 |
| US20210309662A1 (en) | 2021-10-07 |
| JP7515526B2 (ja) | 2024-07-12 |
| ES2926918T3 (es) | 2022-10-31 |
| CY1125576T1 (el) | 2026-02-25 |
| US10906909B2 (en) | 2021-02-02 |
| US20200181146A1 (en) | 2020-06-11 |
| US20240083905A1 (en) | 2024-03-14 |
| WO2017161370A8 (en) | 2018-09-27 |
| HUE059774T2 (hu) | 2023-01-28 |
| JP7023876B2 (ja) | 2022-02-22 |
| US20250179080A1 (en) | 2025-06-05 |
| AU2017235665A1 (en) | 2018-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20221098T1 (hr) | Tretman kognitivnih i simptoma poremećaja raspoloženja kod neurodegenerativnih i neuropsihijatrijskih poremećaja agonistima gabaa receptora koji sadrže alfa5 | |
| MX2021010306A (es) | Gamma-carbolinas heterociclicas fusionadas sustituidas, composiciones farmaceuticas y metodos de uso. | |
| CL2015003444A1 (es) | Compuestos de 3,4 dihidroisoquinolin-2(1h)-ilo | |
| MX379110B (es) | Derivados de azaspiro como antagonistas de trpm8. | |
| BR112015024411A2 (pt) | desaza-purinonas macrocíclicas para o tratamento de infeções virais | |
| EP3504196A4 (en) | METHOD FOR PRODUCING OLAPARIB | |
| MA44737A (fr) | Compositions pour le traitement de troubles liés à l'hyperkératose | |
| CL2014000246A1 (es) | Compuestos derivados fenil-3-aza-biciclo[3.1.0]hex-3-il-metanonas, inhibidores del transportador de glicina (glyt1); composicion farmaceutica que los contiene; combinacion farmaceutica; y su uso en el tratamiento de alzheimer, alteraciones cognitivas en esquizofrenia, psicosis, trastornos psiquiatricos, entre otros | |
| JP2019535799A5 (https=) | ||
| EP3672587A4 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES | |
| EP3324944A4 (en) | INTRAVITREAL AGGREGATION SYSTEMS FOR THE TREATMENT OF EYE DISEASE | |
| HRP20220683T1 (hr) | Liječenje parkinsonove bolesti | |
| EP3419981A4 (en) | COMBINATION THERAPIES FOR THE TREATMENT OF SPINAL MUSCLE ATROPHY | |
| MA43825A (fr) | Schémas posologiques pour le traitement d'infections fongiques | |
| EP2849787A4 (en) | LINGO-2 ANTAGONISTS FOR THE TREATMENT OF DISEASES INVOLVING ENGINE NEURONS | |
| EA201691831A1 (ru) | Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов | |
| EP3405211A4 (en) | ORAL OCTREOTIDE FOR THE TREATMENT OF DISEASES | |
| HUE049556T2 (hu) | Szolúbilis fibroblaszt növekedési faktor receptor 3 (sFGFR3) polipeptid, vázszerkezetinövekedés-retardációs rendellenességek megelõzésében vagy kezelésében történõ alkalmazásra | |
| EA201691788A1 (ru) | Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов | |
| MX2018001592A (es) | Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos. | |
| MA40781A (fr) | Composition pharmaceutique d'isotrétinoïne à faible dosage destinée à la voie orale | |
| MX2019010993A (es) | Derivados de tetrahidroquinolina como antagonistas del receptor p2x7. | |
| CL2016000884A1 (es) | Derivados de piperazina y su uso como medicamento. | |
| EP3533443A4 (en) | FORMULA FOR PERCUTANEOUS ABSORPTION FOR TREATING SLEEP DISORDERS | |
| EP3533451A4 (en) | USE OF PAEONIFLORIN-6'-O-BENZENE SULFONATE IN MEDICINE FOR TREATING SJÖGREN SYNDROME |